Tyra Biosciences Inc (TYRA NASDAQ) stock market data APIs
$10.2103
-0.02(-0.2%)
as of July 10, 2025
Try our APIs with
free plan!
Tyra Biosciences Inc Financial Data Overview
Price chart is built with
Anychart
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Prev. Close
10.2103
Open
10.1872
High
10.398
Low
9.8668
52 wk Range
6.42-29.6
Market Cap
546 M
Shares Outstanding
53 178 K
EPS
-0.47
Beta
1.07
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Tyra Biosciences Inc data using free add-ons & libraries
Get Tyra Biosciences Inc Fundamental Data
Tyra Biosciences Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -113 165 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-29
- EPS/Forecast: -0.4762
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tyra Biosciences Inc News
New
H.C. Wainwright reiterates Buy rating on Tyra Biosciences stock at $30
Investing.com - H.C. Wainwright has reiterated its Buy rating and $30.00 price target on Tyra Biosciences (NASDAQ:TYRA), representing over 200% upside from the current price of $9.57, following the ...
Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)
-TYRA-300 is the only orally administered investigational agent in clinical development for IR NMIBC- -Initial 3-month complete response (CR) data expected to be reported in 1H 2026- CARLSBAD, Calif...
Tyra Biosciences begins dosing in Phase 2 trial for TYRA-300 in bladder cancer
Tyra Biosciences , Inc. (NASDAQ:TYRA), a clinical-stage biotech company with a market capitalization of $484 million, announced Monday that it has dosed the first patient in its SURF302 Phase 2 clinic...
BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug
BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug BofA Securities has upgraded Tyra Biosciences (NASDAQ:TYRA), a clinical-stag...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
